Clinical trial
A Phase IIa Clinical Trial of First-Line Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for Advanced Biliary Tract Cancers With FGFR2 Alterations
NCT07780838 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Clinical Trial of First-Line Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for Advanced Biliary Tract Cancers With FGFR2 Alterations
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 1, 2026
- Completion date
- December 31, 2027
- Enrollment
- 29 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced ampulla of vater carcinoma, locally advanced biliary tract carcinoma, locally advanced extrahepatic cholangiocarcinoma, locally advanced gallbladder carcinoma, locally advanced intrahepatic cholangiocarcinoma, metastatic ampulla of vater carcinoma, metastatic biliary tract carcinoma, metastatic extrahepatic cholangiocarcinoma, metastatic gallbladder carcinoma, metastatic intrahepatic cholangiocarcinoma, stage iii ampulla of vater cancer ajcc v8, stage iii distal bile duct cancer ajcc v8, stage iii gallbladder cancer ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv ampulla of vater cancer ajcc v8, stage iv distal bile duct cancer ajcc v8, stage iv gallbladder cancer ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, unresectable ampulla of vater carcinoma, unresectable biliary tract carcinoma, unresectable extrahepatic cholangiocarcinoma, unresectable gallbladder carcinoma, unresectable intrahepatic cholangiocarcinoma